Results 161 to 170 of about 4,821 (183)

2002-LB: Amycretin, a Novel, Unimolecular GLP-1 and Amylin Receptor Agonist—Results of a Phase 1b/2a Clinical Trial

Diabetes
Introduction and Objective: To investigate the safety, tolerability, pharmacokinetics, and effects on body weight of single- (SAD) and multiple-ascending doses (MAD) of SC amycretin in people with overweight or obesity. Methods: In this single-center, double-blind study (NCT06064006), adults with BMI 27.0-39.9 kg/m2 and HbA1c <6.5%
KIRSTEN DAHL, KASPER ADELBORG, SOHAN DEY, RUBEN DUQUE DO VALE, CASSANDRA KEY, SØREN TOUBRO, ANIA M. JASTREBOFF   +6 more
openaire   +1 more source

2184-LB: Novel Oral Small Molecule ACCG-2671—A Dual Amylin and Calcitonin Receptor Agonist Development Candidate for Obesity Therapy

Diabetes
Introduction and Objective: Amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells in response to food intake, suppresses appetite and delays gastric emptying, making it an attractive target for obesity therapy. Cagrilintide, a long-acting dual amylin and calcitonin receptor agonist (DACRA) peptide, has demonstrated promising ...
XIANKANG FANG, ZHUMING ZHANG, HAIZHEN ZHANG, CHUNLIANG LU, DING XUE, ZIYI WANG, SHANSHAN ZHAN, XIAOYI WANG, WEIFENG LIANG, TENGXIANG MA, NAN HU, JINQIANG J. ZHANG, LIBO CHEN, XINZHONG LAI, DIDI HE, CUI LI, ZHENTING GAO, XICHEN LIN, XINGLONG JIANG, HUI LEI, FANG ZHANG   +20 more
openaire   +1 more source

A structural basis for amylin receptor phenotype

Science, 2022
Jianjun Cao, Matthew J Belousoff, Yi-Lynn Liang   +2 more
exaly  

86-OR: The Amylin Receptor Selective Agonist NN1213 Reduces Food Intake and Body Weight in Rats without Decreasing Calcium Plasma Levels

Diabetes
Introduction and Objective: Amylin analogues are being investigated as potential obesity treatments. Amylin receptors (AMYRs) belong to the calcitonin receptor (CTR) family and consist of heterodimers of the calcitonin receptor and receptor activity modifying proteins (RAMPs). CTR and AMYRs exhibit distinct physiological roles with CTR activation being
DAVID IPSEN, BORJA BALLARIN-GONZALEZ, EE VON MOO, ANNA SECHER, KIRSTEN RAUN   +4 more
openaire   +1 more source

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Boris Böll, Peter Schellongowski   +2 more
exaly  

Glycosylation of Pramlintide: Synthetic Glycopeptides that Display In Vitro and In Vivo Activities as Amylin Receptor Agonists

Chemistry – A European Journal, 2013
Yusuke, Tomabechi, Guy, Krippner, Phillip M, Rendle, Marie A, Squire, Antony J, Fairbanks   +4 more
openaire   +2 more sources

Pharmacotherapy of obesity - Amylin Analogs and Dual Amylin-Calcitonin Receptor Agonists. A literature review

Medical Science
Karolina Woźniak, Michał Stasiak, Adam Woźniak, Franciszek Glapiński, Wiktor Żyro, Katarzyna Żyro   +5 more
openaire   +1 more source

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023
Rujul Parikh, Sagar Lonial
exaly  

SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications

Lancet, The, 2021
Emily Brown, Daniel J Cuthbertson
exaly